Home › Compare › XB vs MRK

XB vs MRK: Dividend Comparison 2026

XB yields 7.20% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XB wins by $1.5K in total portfolio value
10 years
XB
XB
● Live price
7.20%
Share price
$38.92
Annual div
$2.80
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,136.93
Full XB calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — XB vs MRK

📍 XB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXBMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XB + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
XB pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XB
Annual income on $10K today (after 15% tax)
$611.95/yr
After 10yr DRIP, annual income (after tax)
$966.39/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, XB beats the other by $158.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XB + MRK for your $10,000?

XB: 50%MRK: 50%
100% MRK50/50100% XB
Portfolio after 10yr
$31.5K
Annual income
$1,043.61/yr
Blended yield
3.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

XB
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XB buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXBMRK
Forward yield7.20% ✓3.25%
Annual dividend / share$2.80$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$32.2K ✓$30.7K
Annual income after 10y$1,136.93 ✓$950.29
Total dividends collected$9.3K ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: XB vs MRK ($10,000, DRIP)

YearXB PortfolioXB Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,420$719.94$11,192$351.54+$228.00 → XB
2$12,988$768.38$12,524$392.70+$464.00 → XB
3$14,714$816.70$14,015$438.65+$699.00 → XB
4$16,608$864.70$15,682$489.96+$926.00 → XB
5$18,683$912.19$17,547$547.23+$1.1K → XB
6$20,950$959.02$19,632$611.16+$1.3K → XB
7$23,421$1,005.02$21,963$682.53+$1.5K → XB
8$26,111$1,050.08$24,571$762.18+$1.5K → XB
9$29,033$1,094.08$27,486$851.08+$1.5K → XB
10$32,202$1,136.93$30,745$950.29+$1.5K → XB

XB vs MRK: Complete Analysis 2026

XB — Stock

The fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in high-yield, below-investment grade bonds denominated in U.S. dollars of corporate issuers, either directly or indirectly (e.g., through derivatives). It is non-diversified.

Full XB Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this XB vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XB vs SCHDXB vs JEPIXB vs OXB vs KOXB vs MAINXB vs JNJXB vs ABBVXB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.